{Reference Type}: Journal Article
{Title}: A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis.
{Author}: Namba S;Konuma T;Wu KH;Zhou W; ;Okada Y;
{Journal}: Cell Genom
{Volume}: 2
{Issue}: 10
{Year}: Oct 2022 12
暂无{DOI}: 10.1016/j.xgen.2022.100190
{Abstract}: Genomics-driven drug discovery is indispensable for accelerating the development of novel therapeutic targets. However, the drug discovery framework based on evidence from genome-wide association studies (GWASs) has not been established, especially for cross-population GWAS meta-analysis. Here, we introduce a practical guideline for genomics-driven drug discovery for cross-population meta-analysis, as lessons from the Global Biobank Meta-analysis Initiative (GBMI). Our drug discovery framework encompassed three methodologies and was applied to the 13 common diseases targeted by GBMI (N mean = 1,329,242). Individual methodologies complementarily prioritized drugs and drug targets, which were systematically validated by referring previously known drug-disease relationships. Integration of the three methodologies provided a comprehensive catalog of candidate drugs for repositioning, nominating promising drug candidates targeting the genes involved in the coagulation process for venous thromboembolism and the interleukin-4 and interleukin-13 signaling pathway for gout. Our study highlighted key factors for successful genomics-driven drug discovery using cross-population meta-analyses.